ProMIS Neurosciences Book Value per Share

What does ProMIS Neurosciences do? ProMIS Neurosciences develops precision medicine solutions targeting neurodegenerative diseases like Alzheimer’s, ALS, and MSA through proprietary antibody therapeutics. Its product portfolio includes PMN310 for amyloid-beta, PMN267 for TDP-43, and PMN442 for alpha-synuclein, leveraging its ProMIS and Collective Coordinates platforms to identify Disease Specific Epitopes on misfolded proteins. The company focuses on early detection and treatment, with plans to expand into Parkinson's and dementia with Lewy bodies. Its wholly owned subsidiary, ProMIS Neuro, supports these therapeutic development efforts. The firm generates revenue through the development and potential commercialization of its antibody therapeutics, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for neurodegenerative conditions. Its focus on misfolded proteins in diseases like AD, ALS, and MSA positions it to address unmet medical needs in specialized therapeutic segments. The company’s approach combines computational discovery with antibody development to create targeted solutions for complex neurological disorders. ProMIS Neurosciences is one of the most popular companies on Eulerpool.